3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Myelodysplastic Syndromes
2
Melanoma
2
Leukemia, Promyelocytic, Acute
2
Leukemia
2
Hematologic Neoplasms
2
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Neoplasms
1
Hematologic Diseases
1
Interventions
Brentuximab Vedotin
20
Rituximab
10
pirtobrutinib
7
dacetuzumab
7
Doxorubicin
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Lenalidomide
5
Cyclophosphamide
5
ponatinib
4
Imatinib Mesylate
4
Dexamethasone
4
Bendamustine Hydrochloride
4
Azacitidine
4
nilotinib
3
lintuzumab
3
Bortezomib
3
vosaroxin
2
venetoclax
2
spartalizumab
2
pomalidomide
2
ibrutinib
2
Rifampin
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
KW-2478
2
Ifosfamide
2
Gemcitabine
2
Etoposide
2
Dacarbazine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hematologic Diseases
×
Tretinoin
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled